Kliniken & Institute … Kliniken Zentrum für Kinder- und… Welcome Research Pediatric Pulmonology…

Pädiatrische Pneumologie, Allergologie & Mukoviszidose-Zentrum

Forschung der Sektion

Pediatric Pulmonology and Allergology Unit & Cystic Fibrosis Center

I. Research areas in pulmonology, allergology and cystic fibrosis


The purpose of research at the Pediatric Pulmonology and Allergology Unit and Cystic Fibrosis Center is to provide doctors and scientists with a better understanding of the pathogenesis of cystic fibrosis, and to continue improving the diagnosis and therapy of cystic fibrosis and other chronic lung diseases affecting children and adolescents. In order to achieve these objectives, we are currently conducting the following clinical trials some of which were initiated in Heidelberg; we also coordinate the trials in the study and trial network of the German Center for Lung Research (DZL).


In cooperation with the Department of Translational Pulmonology, the Translational Lung Research Center Heidelberg (TLRC) and the Molecular Medicine Partnership Unit (MMPU), our doctors and scientists examine the processes involved in the development of cystic fibrosis, allergies and other chronic lung diseases in order to identify new approaches for therapy. The effectiveness of new treatments is first investigated in various model systems.

Our long-term objective is to transfer the results of this research to our human patients and develop effective therapies for children and adolescents suffering from lung disease.



II. Mitarbeiter

Sowie die Mitarbeiter der Abteilung Translationale Pneumologie.

III. Project funding


Our projects are currently funded by the Federal Ministry of Education and Research (BMBF), the German Center for Lung Research (DZL),  Mukoviszidose e.V. and the Dietmar Hopp Foundation.



IV. Ausgewählte Publikationen

IV. Selected publications


Eichinger M, Optazaite DE, Kopp-Schneider A, Hintze C, Biederer J, Niemann A, Mall MA, Wielputz MO, Kauczor HU, Puderbach M. Morphologic and functional scoring of cystic fibrosis lung disease using MRI. Eur J Radiol 2012;81:1321-1329.

Roth EK, Hirtz S, Duerr J, Wenning D, Eichler I, Seydewitz HH, Amaral MD, Mall MA. The K+ channel opener 1-EBIO potentiates residual function of mutant CFTR in rectal biopsies from cystic fibrosis patients. PLoS ONE 2011;6:e24445.

Sommerburg O, Lindner M, Muckenthaler M, Kohlmueller D, Leible S, Feneberg R, Kulozik AE, Mall MA*, Hoffmann GF*. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population. J Inherit Metab Dis 2010;33:S263-S271. (*equal contribution).

Kreda SM, Mall M, Mengos A, Rochelle L, Yankaskas J, Riordan JR, Boucher RC. Characterization of wild-type and deltaF508 cystic fibrosis transmembrane regulator in human respiratory epithelia. Mol Biol Cell 2005;16:2154-2167

Hirtz S, Gonska T, Seydewitz HH, Thomas J, Greiner P, Kuehr J, Brandis M, Eichler I, Rocha H, Lopes AI, Barreto C, Ramalho A, Amaral MD, Kunzelmann K, Mall M. CFTR Cl- channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 2004;127:1085-1095

Mall M, Kreda SM, Mengos A, Jensen TJ, Hirtz S, Seydewitz HH, Yankaskas J, Kunzelmann K, Riordan JR, Boucher RC. The DeltaF508 mutation results in loss of CFTR function and mature protein in native human colon. Gastroenterology 2004;126:32-41






You may contact us through
Im Neuenheimer Feld 430
69120 Heidelberg

06221 54-8345
06221 56-8806